Phase I study of a neutralizing monoclonal anti-CTLA4 antibody (MDX-010) in patients with relapse of malignancy after allogeneic hematopoietic stem cell transplantation

Bashey, Asad; Medina, Bridget; Zhong, Rui-kun; Zhou, Jiehua; Castro, Januario E.; Holman, Peter; Lane, TA; Sun, Catherine Q.; Lowy, Israel; Corringham, Sue; Soiffer, Robert J.; Mason, James R.; Ball, Edward D.

doi:10.1016/j.bbmt.2004.12.014

Search citation statements

Order By: Relevance

Paper Sections

Select...

Ipilimumab1

Donor Leucocyte Infusions1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2006

2010

Publication Types

Select...

Article2

Book1

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ipilimumab has also been studied in a phase I trial for leukemia and lymphoma patients following relapse from allogeneic stem cell transplant [253]. Seventeen patients were treated and one patient with Hodgkin lymphoma had a complete response and one patient with mantle cell lymphoma had a partial response.…”

Section: Ipilimumabmentioning

confidence: 99%

Macromolecular Anticancer Therapeutics

Reddy¹,

Couvreur²,

Jain³

2010

View full text Add to dashboard Cite

Section: Ipilimumabmentioning

confidence: 99%

Macromolecular Anticancer Therapeutics

Reddy¹,

Couvreur²,

Jain³

2010

View full text Add to dashboard Cite

“…Other approaches include the blockade of CTLA-4 (a negative regulator of T cells) by a neutralizing human monoclonal antibody (ipilimumab). 77 There is some evidence that DLI collected after mobilization with G-CSF results in a reduction of GvHD without a loss of GvL. 78 This approach has been used with some success, even in the setting of haploidentical transplants, particularly if post-DLI immunosuppression is given in addition.…”

Section: Donor Leucocyte Infusionsmentioning

confidence: 99%